Signal Explorer

Auditor Appointment Ratification

Clinical Trial Result Combination Therapy Mentioned Secondary Endpoint Mentioned

Patient Retention High Interim Data Positive Safety Differentiated Fda Aligned Publication Positive Checkpoint Inhibitor Program Expanded Access Program Active

Regulatory Designation Only Clinical Trial Result Combination Therapy Mentioned Secondary Endpoint Mentioned Indication Expansion

Net Loss Reported Earnings Call Replay Details Publication Positive Interim Data Positive Orphan Status Granted Fast Track Designation Received Checkpoint Inhibitor Program Fast Track Granted Safety Differentiated

Ind Submission Planned

Combination Therapy Mentioned Indication Expansion Clinical Trial Result

Net Loss Reported Financing Activities Cash Flow Disclosure Checkpoint Inhibitor Program Inlicensing Deal Completed Competition Disclosure Administrative Efficiency Shares Outstanding Disclosure Discontinued Operations Classification Cash Flow Statement Investing Activities Burn Rate Controlled Interim Data Positive Unrealized Gain Loss Disclosure

Nol Carryforward Expiration Disclosure Nol Tax Credit Carryforward Reimbursement Price Pressure Risk Net Loss Reported Financing Activities Cash Flow Disclosure Checkpoint Inhibitor Program Cybersecurity Breach Reputational Harm Disclosure Tax Cuts And Jobs Act Disclosure Ipo Or Capital Raising Completion Cash Flow Statement Investing Activities Hipaa Fraud Abuse Laws Disclosure Adea Waiver Release

Regulatory Designation Only Combination Therapy Mentioned Indication Expansion

Trial Endpoint Missed

Net Loss Reported Earnings Call Replay Details Interim Data Positive Checkpoint Inhibitor Program Operating Margin Declining Safety Differentiated Enrollment Ahead Of Schedule Publication Positive

Combination Therapy Mentioned Clinical Trial Result Secondary Endpoint Mentioned Indication Expansion

Demand Softening

Utilization Declining Services